Loading clinical trials...
Loading clinical trials...
Evaluation of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration
The objective of this study is to evaluate abicipar pegol for safety and treatment effects in participants with neovascular age-related macular degeneration (AMD).
Age
50 - No limit years
Sex
ALL
Healthy Volunteers
No
Barnet Dulaney Perkins Eye Center
Phoenix, Arizona, United States
Retina Associates Southwest, PC
Tucson, Arizona, United States
Win Retina
Arcadia, California, United States
Retina Consultants of Orange County
Fullerton, California, United States
Mark B. Kislinger, MD, Inc.
Glendora, California, United States
Atlantis Retina Institute (Atlantis Eyecare)
Huntington Beach, California, United States
N. California Retina Vitreous Associates Medical Group, INC.
Mountain View, California, United States
California Eye Specialists Medical Group, Inc
Pasadena, California, United States
Retinal Consultants Medical Group, Inc.
Sacramento, California, United States
Colorado Retina Associates
Golden, Colorado, United States
Start Date
May 25, 2018
Primary Completion Date
February 27, 2019
Completion Date
February 27, 2019
Last Updated
August 3, 2020
124
ACTUAL participants
Abicipar pegol
DRUG
Lead Sponsor
Allergan
NCT05913063
NCT07446582
NCT06779773
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions